Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3966MR)

This product GTTS-WQ3966MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&FCRL5 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001195388.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 83416
UniProt ID P07766; Q96RD9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3966MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ448MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ3893MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ13130MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ2173MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ10988MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ4089MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ15529MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ12725MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-305B83
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW